Yes. Several categories of blood-borne biomarkers shift measurably before visible signs of premature aging appear — which means a well-chosen panel can identify accelerated aging trajectories while they're still reversible.
The categories with the strongest peer-reviewed support:
- Chronic inflammation — hs-CRP is the most-studied blood marker of the inflammaging pattern that structurally accelerates aging across tissues (Franceschi, 2000).
- Glycation load — HbA1c and fasting glucose reflect the Maillard reaction damaging long-lived proteins (Monnier, 1990).
- Metabolic strain — fasting insulin often shifts years before other glucose markers do (DiNicolantonio, 2017).
- Hormonal decline — estradiol trajectory in perimenopausal women predicts subsequent tissue and skin changes (Brincat, 1983).
- Oxidative stress and repair capacity — vitamin D status supports DNA damage repair (Bikle, 2011); omega-3 index supports membrane integrity and inflammatory tone (Harris, 2004).
Epigenetic age tests (biological age from DNA methylation) are also available now and are a rapidly maturing category of premature-aging measurement, though they're separate from the metabolic and hormonal markers above.
The nine biomarkers on the JenSkin panel are chosen specifically because each has peer-reviewed evidence for accelerating a specific mechanism of skin aging in women — and together they give you a data-informed picture of whether your biology is aging on-trajectory, ahead of it, or behind it.